Skip to content

Concomitant Therapy of H. Pylori

Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01922765
Enrollment
540
Registered
2013-08-14
Start date
2013-08-31
Completion date
2014-02-28
Last updated
2014-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis, Gastric Ulcer, and Duodenal Ulcer

Keywords

Helicobacter, Eradication

Brief summary

If we compare eradication rate of Helicobacter pylori divided to 4 groups: amoxicillin, rabeprazole, clarithromycin(AOC), amoxicillin, rabeprazole, metronidazole(AOM), treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days(sequential), amoxicillin, clarithromycin, metronidazole, rabeprazole(concomitant), then the eradication rate of concomitant group will be the highest.

Detailed description

* Subject: The patient of gastritis, gastric ulcer, and duodenal ulcer infected with Helicobacter pylori * 170 subjects per group * Eradication regimens are as follows: AOC group, treated with amoxicillin, rabeprazole, clarithromycin for 7 days; AOM group, treated with amoxicillin, rabeprazole, metronidazole for 7 days; sequential group, treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days; concomitant group, treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days

Interventions

DRUGamoxicillin, clarithromycin, metronidazole, rabeprazole

Sponsors

Bucheon St. Mary's Hospital
CollaboratorOTHER
St Vincent's Hospital
CollaboratorOTHER
The Catholic University of Korea
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients infected with Helicobacter pylori

Exclusion criteria

* cancer * pregnancy * formerly treated with eradication

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori6 months (Feb 2014)measure eradication rate of H.pylori with urea breath test(UBT) after 6 to 8 weeks of treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026